Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
Grenfell RFQ, Almeida NBF, Filgueiras PS, Corsini CA, Gomes SVC, de Miranda DAP, Lourenço AJ, Martins-Filho OA, de Oliveira JG, Teixeira-Carvalho A, Campos GRF, Nogueira ML, Alves PA, Fernandes GR, Castilho LR, Lima TM, de Abreu DPB, Alvim RGF, Silva TBS, Jeremias WJ, Otta DA, Campi-Azevedo AC; Immunita-001 Team.
Grenfell RFQ, et al. Among authors: alves pa.
Front Immunol. 2022 Jun 9;13:918896. doi: 10.3389/fimmu.2022.918896. eCollection 2022.
Front Immunol. 2022.
PMID: 35757764
Free PMC article.
Clinical Trial.